TOP 100 MEDICAL SITES
| |||
|
| |||
| |||
|
| |||
| Repros Therapeutics: Circling the Drain to Zero Repros Therapeutics (RPRX) is a nearly-defunct biotech company best described in ER terms as CTD (circling the drain). Despite this, it spikes periodically on rumors of I know not what. For the last few days it’s had a low of $0.88 and a high of $1.12. There are options available (unusual for a low-priced stock), meaning you can buy puts instead of shorting. (Shares are hard to borrow and the stock moves fast, so puts are definitely the safer way to play this.) The November 2.5 puts appear to be the clearest play. They have been generally purchasable in the $1.75 area or below. So maximum profit is $0.75 if the stock goes to zero, or more likely $0.70 if the stock trades at a nickel after a bankruptcy filing. Break even is if the stock trades at $0.75 in November. Maximum loss is if the stock trades at or above $2.50 at expiration. Complete Story » seekingalpha.com |
Insider Selling at Vivus Not Yet Cause for Alarm Ruthanne Williams Roussel submits:There’s a good argument to be made that insider buys are a stronger predictor of stock movements than insider sales. To boil it down, there are two basic reasons for this, which we can see by taking a look at Vivus Inc. (VVUS) as an example. There are lots of reasons an insider, who may have quite a big chunk of his net worth tied up in a given stock, may have to sell, but really only one reason to buy: he thinks it’s going up.Complete Story » seekingalpha.com |
Panel Recommends Cervarix A U.S. federal advisory panel recommended that GlaxoSmithKline's Cervarix vaccine be used in girls and women to prevent cervical cancer. online.wsj.com |
Generic-Drug Makers Protest Supply Limits The FTC expressed concern about the practices of brand-name drug makers after generic drug companies complained they can't get bulk supplies of some medicines they want to copy. online.wsj.com |
Biotech Exits 2009 with a Whimper The Burrill Report submits: by MARIE DAGHLIANThe last week of a turbulent year ended on a quiet note with a smattering of financings and one major deal. Bunge (BG), a major supplier of raw materials and services to the biofuels industry, expanded its sugar and bioenergy business in Brazil. The global agribusiness company entered into a $1.5 billion stock swap to become the sole owner of Usina Moema Participaoes, a holding company that owns one sugarcane mill in Brazil and has ownership interests in five others. The deal gives Bunge a 60 percent effective share of the total annual capacity of the six mills, which is 15.4 million metric tons. Complete Story » seekingalpha.com |